Molecular Breakthrough: Targeted Inhibition of PKM2 Pathway Halts Growth of Treatment-Resistant Leukemia Stem Cells

Researchers identify the PKM2 pathway as a metabolic "achilles heel" for leukemia stem cells, offering a new way to prevent cancer relapse and improve survival.

By: AXL Media

Published: Feb 24, 2026, 8:50 AM EST

Source: The information in this article was sourced from News Medical

Targeting the Root of Cancer Relapse

While modern chemotherapy can often eliminate the bulk of cancerous white blood cells, Acute Myeloid Leukemia (AML) remains notoriously difficult to cure due to a small population of resilient leukemia stem cells (LSCs). These "master cells" frequently survive standard treatments, remaining dormant in the bone marrow before eventually triggering a relapse. According to the research published in February 2026, a team of scientists has identified a metabolic vulnerability within these stem cells. By focusing on how LSCs process energy, the team discovered a way to specifically target the "roots" of the cancer without harming healthy blood-forming cells.

The Critical Role of the PKM2 Enzyme

The study centers on an enzyme called Pyruvate Kinase M2 (PKM2), which serves as a vital regulator of metabolism in cancer cells. According to the research findings, leukemia stem cells are uniquely dependent on PKM2 to maintain their ability to divide and multiply. While healthy cells typically use a different form of this enzyme, LSCs rely on the specific chemical signals of PKM2 to support their rapid energy demands. By utilizing high-resolution molecular screening, the researchers were able to confirm that LSCs express significantly higher levels of this protein compared to their healthy counterparts, marking it as a clear therapeutic target.

Interrupting the Metabolic Engine of Stem Cells

By applying a specialized chemical inhibitor designed to block PKM2 activity, the researchers were able to effectively "starve" the leukemia stem cells. According to the study, this inhibition does more than just slow down growth, it actively triggers a process of cellular death within the stem cell population. Without the metabolic support provided by PKM2, the LSCs lose their ability to self-renew, which is the primary mechanism they use to repopulate the blood with cancerous cells. This metabolic blockade represents a shift in strategy from broad-spectrum chemotherapy to precision metabolic warfare.